Harshika Sarbajna BE, MBA

Harshika Sarbajna is the global head of anti-infectives for Sandoz, a Novartis Division. In this role, she is responsible for ensuring sustainable growth of the antibiotics portfolio at Sandoz, the largest provider of generic antibiotics globally, working closely with markets and various functions within Sandoz. In this role, she is also spearheading Sandoz & Novartis wide AMR Stewardship program, bringing together stakeholders both inside and outside the organization.

She previously served as the global head of strategy and operations of the Biosimilars business unit within Sandoz and was part of the business leadership team. During Harshika’s tenure, she successfully led development and implementation of the commercial, portfolio and manufacturing strategy of the biosimilars business that delivered two successful biosimilar launches in Europe, and double-digit growth of in-market products across the globe.

Prior to Sandoz, Ms. Sarbajna served as the head of business strategy for the biosimilars business at Dr. Reddy’s Lab and drove growth across the portfolio in key markets including US, Asia, Latin America, and Russia. Before joining Dr. Reddy’s, she led various executive-level advisory engagements on business and growth strategy for large Corporates and PE funds as a principal consultant with The Parthenon Group.